The Challenge & Strategy
Bristol Myers Squibb faced mounting pressure from increasing operational complexity, patent cliffs, and rising customer expectations, demanding a systematic, enterprise-wide approach to process excellence.
Over a two-year implementation journey, BMS built a mature Business Process Management (BPM) capability as the foundation for its continuous improvement system, embedding it across more than 8,000 employees in R&D and drug development operations.
The strategy combined Lean, Six Sigma, Agile, and Design Thinking methodologies with an integrated portfolio management approach, aligning improvement projects to broader organizational strategic objectives through a Business Process Council, an executive forum of cross-functional drug development leaders providing end-to-end governance and visibility.
The Project
BMS deployed a multi-layered engagement model. For example, Design Thinking workshops with Global Process Owners, Agile sprint-based improvement cycles, and a train-the-trainer Strategy Execution Methodology to upskill change agents across the organisation.
A digital BPM platform provided real-time tracking of projects and results, while structured tollgate reviews ensured accountability at every phase. Over 1,200 employees participated in 'Translating Strategy to Execution' training, and more than 300 grassroots improvement initiatives were launched by frontline employees and mid-level managers, demonstrating genuine ownership at all levels. AI capabilities were also integrated into the BPM tool to further enhance its impact.
The Results
More than $295M in combined cost savings and avoidance delivered, and over 30% efficiency gains and accelerated drug development cycle times achieved
Customer satisfaction scores improved by 18% and employee engagement increased by 15%
95% organizational awareness of the BPM program achieved and over 300 grassroots improvement initiatives launched by employees across the enterprise
The results reflect a two-year transformation featuring continuous improvement as a core way of working across BMS's global drug development operations.
Benefits Achieved
Financial Impact: Over $295M in combined cost savings and avoidance, directly supporting strategic objectives.
OPEX: Faster drug development cycles and improved reliability, delivering medicines to patients more quickly.
Cultural Transformation: Continuous improvement embedded into organizational DNA, with data-driven decision-making and collaborative problem-solving as standard.
Scalable Capability: The BPM model has been replicated across multiple business units and geographies, maintaining global standards while adapting to local needs.
Strategic Gains: BPM established as a core strategic differentiator, directly aligned to BMS's goals of cost optimization, digital transformation, and patient-centric care delivery.